A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 55

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2018

Summary

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - A disintegrin and metalloproteinase with thrombospondin motifs 5 or ADAMTS5 is an enzyme encoded by the ADAMTS5 gene. It plays an important role in the destruction of aggrecan in arthritic diseases and in proteolytic processing mostly during the peri-implantation period.

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 3 respectively.

Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Joint Pain and Seasonal Allergic Rhinitis.

The latest report A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H1 2018, outlays comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)

- The report reviews A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects

- The report assesses A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Overview
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Eli Lilly and Co
Galapagos NV
GlaxoSmithKline Plc
Merck KGaA
Paradigm Biopharmaceuticals Ltd
Rottapharm Biotech Srl
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Drug Profiles
ALX-1141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRB-0017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLPG-1972 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2394002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADAMTS4 and ADAMTS5 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Dormant Products
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
May 17, 2018: Phase 2b Osteoarthritis Clinical Trial Ahead of Schedule with 80% Recruited
Apr 27, 2018: Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018
Apr 17, 2018: Merck to Present Data on its ADAMTS-5 inhibiting nanobody M6495 at OARSI 2018 World Congress
Mar 27, 2018: Paradigm Phase 2 Clinical Data - Update
Mar 01, 2018: Paradigm Reports Osteoarthritis Pain Reduced by 50%
Jan 16, 2018: European Patent Granted for Bone Marrow Edema Lesions
Jan 07, 2018: Galapagos: Positive top line results with GLPG1972 in osteoarthritis patients
Nov 23, 2017: Paradigm's Two Arthritis Phase 2 Clinical Trials on Schedule
Nov 14, 2017: Paradigm Reports Successful Phase 2a BML/ACL Clinical Trial Results
Nov 05, 2017: Galapagos Provides Update On Its Investigational Drug GLPG1972 at ACR Annual Meeting 2017
Oct 30, 2017: First Participant Successfully Dosed in Phase 2b Clinical Trial for Osteoarthritis
Sep 19, 2017: Ethics Approval Received for Phase 2b Clinical Trial for Osteoarthritis
Sep 14, 2017: Paradigm Biopharmaceuticals: Significant momentum with Phase 2 Ross River Virus Clinical Trial
Sep 11, 2017: A Paradigm Shift In Treating Osteoarthritis Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Galapagos NV, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Merck KGaA, H1 2018
Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
Pipeline by Rottapharm Biotech Srl, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Metconazole Fomulation Market Insights, Forecast to 2025
    Published: 07-Nov-2018        Price: US 3900 Onwards        Pages: 118
    This report studies the global market size of Metconazole Fomulation in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Metconazole Fomulation in these regions. This research report categorizes the global Metconazole Fomulation market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market ......
  • Global Myclobutanil Market Insights, Forecast to 2025
    Published: 07-Nov-2018        Price: US 3900 Onwards        Pages: 119
    This report studies the global market size of Myclobutanil in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Myclobutanil in these regions. This research report categorizes the global Myclobutanil market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and cha......
  • Global Triadimenol Market Insights, Forecast to 2025
    Published: 07-Nov-2018        Price: US 3900 Onwards        Pages: 111
    This report studies the global market size of Triadimenol in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Triadimenol in these regions. This research report categorizes the global Triadimenol market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challe......
  • Global Oral hypoglycemic agents and insulin analogues Market Insights, Forecast to 2025
    Published: 07-Nov-2018        Price: US 3900 Onwards        Pages: 113
    This report studies the global market size of Oral hypoglycemic agents and insulin analogues in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oral hypoglycemic agents and insulin analogues in these regions. This research report categorizes the global Oral hypoglycemic agents and insulin analogues market by players/brands, region, type and application. This report also studies the global market status, ......
  • Global Vegetarian Based Capsules Market Insights, Forecast to 2025
    Published: 07-Nov-2018        Price: US 3900 Onwards        Pages: 115
    This report studies the global market size of Vegetarian Based Capsules in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Vegetarian Based Capsules in these regions. This research report categorizes the global Vegetarian Based Capsules market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends......
  • Global Essential Fatty Acids Market Research Report 2018
    Published: 07-Nov-2018        Price: US 2900 Onwards        Pages: 118
    This report studies the global Essential Fatty Acids market status and forecast, categorizes the global Essential Fatty Acids market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - BASF SE - FMC Corporation - The Dow Chemical Company - Koni......
  • Global Torsemide Market Research Report 2018
    Published: 07-Nov-2018        Price: US 2900 Onwards        Pages: 113
    This report studies the global Torsemide market status and forecast, categorizes the global Torsemide market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Cayman - LGC - BOCSCI Inc. Geographically, this report studies the top prod......
  • Global Alimta Market Research Report 2018
    Published: 07-Nov-2018        Price: US 2900 Onwards        Pages: 119
    This report studies the global Alimta market status and forecast, categorizes the global Alimta market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Eli Lilly - Abbott Healthcare - Cadila Healthcare Geographically, this report stu......
  • Global Mitochondrial Myopathy Diagnosis & Treatment Market Research Report 2018
    Published: 07-Nov-2018        Price: US 2900 Onwards        Pages: 115
    This report studies the global Mitochondrial Myopathy Diagnosis & Treatment market status and forecast, categorizes the global Mitochondrial Myopathy Diagnosis & Treatment market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Centogene AG - GeneDx......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs